Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...